WE ARE IN A NEW ERA IN OUR GLOBAL WAR AGAINST CANCER
Cancers are able to develop protective shields, thus rendering our body immune system unable to recognize and fight cancer cells. Cancer immunotherapy breaks down these shields and trains our body own defenses to find and destroy cancer cells.
Immunotherapy has become an established pillar of cancer treatment at Onco Life Centre with significantly improved treatment outcomes for our patients with a broad variety of cancers. Our Oncologists at Onco Life Centre work in close collaboration with Cancer Genomics Experts in the US to perform cancer gene mapping and DNA sequencing on our patients’ cancer tissue. Regular teleconferencing and live exchange of information with the US Genomics Experts allows our Oncologists to specifically design unique treatment plans that have resulted in significant improvements in the cancer responses and survival of our patients.
How does immunotherapy help the immune system fight cancer?
Antigens are toxins or foreign substances that trigger an immune response, especially in the production of antibodies. Antigens are targeted by antibodies. Each antibody is specifically produced by the immune system to precisely match an antigen, and this leads to the initiation of a tailored immune response.
Immune checkpoints are regulators of the immune system. These pathways prevent the immune system from attacking your own healthy cells indiscriminately. However, cancer can find ways to hide from the immune system by activating these immune checkpoint targets. Checkpoint inhibitor is a form of immunotherapy that can block inhibitory checkpoints, which will amplify your body’s immune system to help destroy cancer cells. Common checkpoints that these inhibitors affect are the PD-1/PD-L1 and CTLA-4 pathways. Immunotherapy treatments can be used as a monotherapy or in combination with other cancer treatments.
What cancers are treated with immune checkpoint inhibitors?
Last year capped an incredible decade for cancer immunotherapy. Patients with more than a dozen types of cancer can now receive FDA-approved immunotherapies.
At Onco Life Centre, our oncologists will specifically design your treatment plan, using such latest breakthroughs in cancer therapy.
Immune checkpoint inhibitors are approved to a variety of cancer types, including:
How does targeted cancer therapy work?
Precision medicine is the use of genetic changes in a patient’s tumour to determine a cancer treatment most likely for the tumour to respond to.
Cancer genomics profiling helps our Oncologists at Onco Life Centre to identify the best targeted therapy for your cancer illness.
Once specific changes in your cancer genes and proteins have been identified, our Oncologist will discuss with you on the best treatment strategies, as well as help you understand the treatment tolerability and estimated drug cost.
1) Types of targeted cancer therapy based on mechanism of action
Monoclonal antibodies
Targeted cancer therapy |
Mechanism of action |
---|---|
EGFR inhibitors |
Some cancers make too much of a protein called EGFR. EGFR inhibitors work by attaching to the end of EGFR (a cell surface receptor) to block the action of EGF |
HER2 inhibitors and conjugates |
20–25% of breast cancers have too much of a protein called HER2. HER2 inhibitors work by attaching to the end of HER2 (a transmembrane receptor) to stop HER2 from attaching to other receptors |
Small molecules
Targeted cancer therapy |
Mechanism of action |
---|---|
Kinase inhibitors |
Kinases are molecules that help send growth signals in cancer cells. Kinase inhibitors work by blocking the action of receptor tyrosine kinases |
mTOR inhibitors |
mTOR is a protein kinase within a cell. In cancer cells, they may be actively promoting their growth. mTOR inhibitors enter the cells and block the activity of mTOR |
PARP inhibitors |
PARP protein helps repair damaged DNA in cancer cells. PARP inhibitors act by stopping PARP proteins from repairing DNA in cancer cells |
Others
Targeted cancer therapy |
Mechanism of action |
---|---|
VEGF inhibitors |
Cancer cells release VEGF to form new blood vessels for growth. VEGF inhibitors attach to VEGF to stop it from attaching to VEGF receptor on cancer cells, stopping them from growing |
2) Types of cancer that respond to targeted therapy based on the specific changes identified in your cancer genes and proteins
NSCLC (Non-small cell lung cancer)
Gene / protein identified: ALK, BRAF, EGFR, MET, RET, ROS1, PDL1, TNB, KRAS G12C ,NTRK 1-3, HER-2 |
Breast cancer
Gene / protein identified: BRCA1, BRCA2, ER/PR, erBB2/HER-2, PIK3CA, PDL1, MSI, TNB, PALB2, PTEN |
Colorectal cancer
Gene / protein identified: RAS (negative predictor), HER2, BRAF, MSI, TNB, KRAS G12C, NTRK 1-3 |
Prostate cancer
Gene / protein identified: Androgen receptor, BRCA1, BRCA2, PALB2, MSI, TNB, CDK12, NTRK 1-3 |
Ovarian cancer
Gene / protein identified: BRCA1, BRCA2, PALB2, RAD51 C/D, BRIP1 |
Gastrointestinal stromal tumour
Gene / protein identified: C-KIT, PDGFR |
Gastric cancer & Oesophageal
Gene / protein identified: erBB2/HER-2, PDL1, MSI, TNB, BRCA1, BRCA2, PALB2 |
Bladder cancer
Gene / protein identified: FGFR2/3, PIK3CA, TSC1 |
MSI-H or dMMR solid tumours and colorectal cancer
Gene / protein identified: MSI-H or dMMR |
Pancreatic cancer
Gene / protein identified: BRCA1, BRCA2, PALB2, ATM, MSI, PDL1, TMB, KRAS, NRAS, NTRK 1-3, ALK |
Medullary thyroid cancer
Gene / protein identified: RET |
Biliary tract cancer (Cholangiocarcinomas)
Gene / protein identified: BRAF, FGFR 1-3, MSI, TMB, NTRK 1-3, PIK3CA, BRCA1, BRCA2, PALB2, ATM, MET |
Solid tumors with NTRK fusions
Gene / protein identified: NTRK |
Cervical cancer
Gene / protein identified: PDL1, TMB, MSI, HER-2, NTRK 1-3 |
Anaplastic thyroid cancer
Gene / protein identified: BRAF |
Uterine (Endometrial) cancer
Gene / protein identified: HER-2, PIK3CA, NTRK 1-3, BRCA1, BRCA2, PALB2, ATM, PDL1, TMB, MSI |
Kidney (Renal) cancer
Gene / protein identified: CMET, BRCA1, BRCA2, PALB2, ATM, NTRK 1-3 |
Soft Tissue Sarcoma
Gene / protein identified: BRCA1, BRCA2, PALB2, ATM, NTRK 1-3, ALK, PDL1, TMB, MSI |